A Phase 4 interventional study of Infanrix hexa and Prevnar13 in Acellular Pertussis, Tetanus and Poliomyelitis, sponsored by GlaxoSmithKline. Completed at 30 sites in 6 countries. Open to participants aged 6 Weeks to 14 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-09.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Tetanus — none open to participants now, none under way, none of them phase 3. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Tetanus.
Among the 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Tetanus, this one is the 4th largest by enrollment, is one of 2 that started in 2016, is one of 6 in phase 4, and was the 13th registered.
319 studies on the registry are indexed under Tetanus; 30 are open to participants now.
Browse Tetanus studies →None of the 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Tetanus is open now. The open studies under Tetanus, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 16 Tetanus studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 6 Weeks to 14 Weeks · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2016.
This study's enrollment of 601 is above the median of 420 across 281 interventional studies indexed under Tetanus.
Median enrollment 494 across the 15 interventional studies. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 2 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
106 studies in Tetanus by GlaxoSmithKline: none open now, 1 under way, 1 of them phase 3. Of 104 finished, 62 (60%) have results posted.
Among the 106 studies in Tetanus by GlaxoSmithKline, this one is the 31st largest by enrollment of the 98 interventional ones that give a count, is one of 4 that started in 2016, is one of 22 in phase 4, and was the 94th registered.
GlaxoSmithKline’s Tetanus studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Tetanus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 106 in Tetanus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' Infanrix hexa, given in the primary vaccination schedule to infants born to pregnant women who participated in study 116945 [DTPA (BOOSTRIX)-047]. This study will help us evaluate if the presence of transplacentally transferred maternal antibodies interfere with the immune response to primary vaccination with Infanrix hexa and a co-administered pneumococcal conjugate vaccine given as a part of this study in infants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Medically stable* prematurely born infants, born after a gestation period of 27-36 weeks may be enrolled in the study at the discretion of the investigator.
Exclusion Criteria:
A vaccine not foreseen by the study protocol administered during the period starting from 30 days before each dose of vaccine and ending 30 days after*, with the exception of inactivated influenza vaccine and other vaccines given as a part of the national/regional immunisation schedule, that are allowed at any time during the study period.
Acute disease and/or fever at the time of enrolment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group will consist of infants born to mothers belonging to the dTpa Group in study 116945 \[DTPA (BOOSTRIX)-047\] i.e. who received a single dose of BoostrixTM during pregnancy and a dose of placebo immediately post-delivery. All infants in this group will receive Infanrix hexaTM co-administered with Prevenar 13®.
Biological: Infanrix hexa · Drug: Prevnar13
This group will consist of infants born to mothers belonging to the Control group in study 116945 \[DTPA (BOOSTRIX)-047\], i.e. who received a single dose of placebo during pregnancy and a dose of BoostrixTM immediately post-delivery. All infants in this group will receive Infanrix hexaTM co-administered with Prevenar 13®.
Biological: Infanrix hexa · Drug: Prevnar13
• All subjects will receive Infanrix hexa at 2 and 4, at 3 and 5, at 2, 4 and 6 months or at 2, 3 and 4 months, depending on the immunisation schedule of the country. Infanrix hexa is administered intramuscularly to the right thigh.
• All subjects will receive Infanrix hexa co-administered with Prevenar13\* at 2 and 4, at 3 and 5, at 2, 4 and 6 months or at 2, 3 and 4 months, depending on the immunisation schedule of the country. \*In some countries/regions with an Infanrix hexa 3-dose vaccination schedule, Prevenar 13 could be administered as 2-doses or 3-doses primary vaccination schedule (according to the routine national immunisation schedule). Prevnar13 is administered intramuscularly to the left thigh.
Number of Subjects With Vaccine Response Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) Antigens
Vaccine response to the PT, FHA and PRN antigens, is defined as the appearance of antibodies in subjects who were initially seronegative (i.e., with concentrations lower than (\<) the cut-off value of the assay), or at least maintenance of pre-vaccination antibody concentrations in subjects who were initially seropositive (i.e., with concentrations greater than or equal to (≥) the cut-off value of the assay). Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, 2.187 IU/mL for anti-PRN.
Time frame: 1 month after the last dose of the primary vaccination
Number of Seroprotected Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentration Above or Equal to the Assay Cut-off
A seroprotected subject is a subject whose antibody concentration/titre was ≥ the level defining clinical protection, of 0.1 International Units per milliliter (IU/mL).
Time frame: 1 month after the last dose of the primary vaccination
Number of Seroprotected Subjects With Anti Hepatitis B (Anti-HBs) Antibody Concentration Above or Equal to the Assay Cut-off
A seroprotected subject is a subject whose antibody concentration/titre was ≥ to the level defining clinical protection, of 10 micro International Units per milliliter (mIU/mL).
Time frame: 1 month after the last dose of the primary vaccination
Number of Seroprotected Subjects With Anti-poliovirus Type 1, 2 and 3 Antibody Concentration Above or Equal to 8
A seroprotected subject is a subject whose antibody titre was ≥ the level defining clinical protection, of 8 ED50.
Time frame: 1 month after the last dose of the primary vaccination
Number of Seroprotected Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Above or Equal to the Assay Cut-off
A seroprotected subject is a subject whose antibody concentration/titre was ≥ the level defining clinical protection, of 0.15 micrograms per milliliter (µg/mL).
Time frame: 1 month after the last dose of the primary vaccination
Number of Seroprotected Subjects Against Diphtheria (Anti-D) and Tetanus (Anti-T) Antibody Concentration Above or Equal to the Assay Cut-off.
A seroprotected subject is a subject whose antibody concentration was ≥ the level defining clinical protection, of 0.1 IU/mL.
Time frame: Before the first dose of Infanrix hexa
Anti-D and Anti-T Antibody Concentrations
Antibody concentrations were expressed as geometric mean concentrations (GMCs) and measured in IU/mL.
Time frame: Before the first dose of Infanrix hexa
Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Antibody Concentration Above or Equal to the Assay Cut-off.
A seropositive subject is a subject whose antibody concentration is ≥ the assay cut-off defined. Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA,2.187 IU/mL for anti-PRN
Time frame: Before the first dose of Infanrix hexa
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
Anti-PT, anti-FHA and anti-PRN antibody concentrations were expressed as GMCs and measured in IU/mL.
Time frame: Before the first dose of Infanrix hexa
Anti-D and Anti-T Antibody Concentrations
Antibody concentrations were expressed as geometric mean concentrations (GMCs) and measured in IU/mL.
Time frame: 1 month after the last dose of the primary vaccination
Anti-Polio Type 1, 2 and 3 Antibody Titers
Anti-Polio type 1, 2 and 3 antibody titers were expressed as geometric mean titers (GMT).
Time frame: 1 month after the last dose of the primary vaccination
Anti-HBs Antibody Concentrations
Anti-HBs antibody concentrations were expressed as geometric mean concentrations (GMCs) and measured in mIU/mL.
Time frame: 1 month after the last dose of the primary vaccination
Anti-PRP Antibody Concentrations
Anti-PRP antibody concentrations were expressed as GMCs and measured in µg/mL.
Time frame: 1 month after the last dose of the primary vaccination
Anti-PT, Anti-FHA, Anti-PRN Antibody Concentrations
Anti-PT, anti-FHA, anti-PRN antibody concentrations were expressed as GMCs and measured in IU/mL.
Time frame: 1 month after the last dose of the primary vaccination
Anti-pneumococcal Antibody Concentrations
Assessed anti-pneumococcal serotypes were (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F), expressed as GMCs and measured in µg/mL.
Time frame: 1 month after the last dose of the primary vaccination
Number of Subjects With Anti-PT, Anti-FHA, Anti-PRN Antibody Concentration Above or Equal to the Assay Cut-off.
A seropositive subject is a subject whose antibody concentration is ≥ the assay cut-off defined. Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA,2.187 IU/mL for anti-PRN
Time frame: 1 month after the last dose of the primary vaccination
Number of Subjects With Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Solicited local symptoms were assessed by each and across dose.
Time frame: During the 4-day (Day 0-Day 3) follow-up period after each vaccination
Number of Subjects With Solicited General Symptoms
Assessed solicited general symptoms were drowsiness, irritability/fussiness, loss of appetite and fever \[defined as axillary route temperature ≥ 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Solicited general symptoms were assessed by each and across dose.
Time frame: During the 4-day (Day 0-Day 3) follow-up period after each vaccination
Number of Subjects With Unsolicited Adverse Events
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: During the 31-day (days 0-30) follow-up period after each vaccination
Number of Subjects With Serious Adverse Events (SAEs)
SAEs assessed included medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity.
Time frame: From Day 0, prior to vaccination until the study end, at Month 3 or 5 (depending on vaccination schedule of the country)
| Milestone | dTpa Group | Control Group |
|---|---|---|
| Started | 296 | 305 |
| Completed | 291 | 301 |
| Not completed | 5 | 4 |
| Withdrew: Serious adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Migrated/moved from study area | 3 | 1 |
| Withdrew: Subject vaccinated outside of the study | 0 | 1 |
Vaccine response to the PT, FHA and PRN antigens, is defined as the appearance of antibodies in subjects who were initially seronegative (i.e., with concentrations lower than (\<) the cut-off value of the assay), or at least maintenance of pre-vaccination antibody concentrations in subjects who were initially seropositive (i.e., with concentrations greater than or equal to (≥) the cut-off value of the assay). Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, 2.187 IU/mL for anti-PRN.
| Participants | dTpa Group | Control Group |
|---|---|---|
| anti-PT antibody | 185 | 249 |
| anti-FHA antibody | 95 | 238 |
| anti-PRN antibody | 90 | 225 |
A seroprotected subject is a subject whose antibody concentration/titre was ≥ the level defining clinical protection, of 0.1 International Units per milliliter (IU/mL).
| Participants | dTpa Group | Control Group |
|---|---|---|
| anti-D antibody | 264 | 271 |
| anti-T antibody | 266 | 271 |
A seroprotected subject is a subject whose antibody concentration/titre was ≥ to the level defining clinical protection, of 10 micro International Units per milliliter (mIU/mL).
| Participants | dTpa Group | Control Group |
|---|---|---|
| Number of Seroprotected Subjects With Anti Hepatitis B (Anti-HBs) Antibody Concentration Above or Equal to the Assay Cut-off | 251 | 259 |
A seroprotected subject is a subject whose antibody titre was ≥ the level defining clinical protection, of 8 ED50.
| Participants | dTpa Group | Control Group |
|---|---|---|
| anti-Polio 1 antibody | 233 | 242 |
| anti-Polio 2 antibody | 239 | 235 |
| anti-Polio 3 antibody | 228 | 236 |
A seroprotected subject is a subject whose antibody concentration/titre was ≥ the level defining clinical protection, of 0.15 micrograms per milliliter (µg/mL).
| Participants | dTpa Group | Control Group |
|---|---|---|
| Number of Seroprotected Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Above or Equal to the Assay Cut-off | 255 | 256 |
A seroprotected subject is a subject whose antibody concentration was ≥ the level defining clinical protection, of 0.1 IU/mL.
| Participants | dTpa Group | Control Group |
|---|---|---|
| anti-D antibody | 200 | 110 |
| anti-T antibody | 240 | 225 |
Antibody concentrations were expressed as geometric mean concentrations (GMCs) and measured in IU/mL.
| IU/mL | dTpa Group | Control Group |
|---|---|---|
| anti-D antibody | 0.423 (0.354 to 0.506) | 0.089 (0.076 to 0.103) |
| anti-T antibody | 2.152 (1.925 to 2.406) | 0.378 (0.330 to 0.434) |
A seropositive subject is a subject whose antibody concentration is ≥ the assay cut-off defined. Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA,2.187 IU/mL for anti-PRN
| Participants | dTpa Group | Control Group |
|---|---|---|
| anti-PT antibody | 218 | 88 |
| anti-FHA antibody | 242 | 210 |
| anti-PRN antibody | 231 | 151 |
Anti-PT, anti-FHA and anti-PRN antibody concentrations were expressed as GMCs and measured in IU/mL.
| IU/ml | dTpa Group | Control Group |
|---|---|---|
| anti-PT antibody | 11.9 (10.3 to 13.6) | 2.2 (2.0 to 2.5) |
| anti-FHA antibody | 88.3 (77.7 to 100.4) | 6.6 (5.7 to 7.7) |
| anti-PRN antibody | 70.5 (56.1 to 88.5) | 4.5 (3.7 to 5.4) |
Antibody concentrations were expressed as geometric mean concentrations (GMCs) and measured in IU/mL.
| IU/ml | dTpa Group | Control Group |
|---|---|---|
| anti-D antibody | 1.747 (1.598 to 1.910) | 2.746 (2.502 to 3.015) |
| anti-T antibody | 2.347 (2.135 to 2.582) | 2.278 (2.069 to 2.508) |
Anti-Polio type 1, 2 and 3 antibody titers were expressed as geometric mean titers (GMT).
| Titers | dTpa Group | Control Group |
|---|---|---|
| anti-Polio 1 antibody | 432.1 (351.8 to 530.9) | 489.9 (402.6 to 596.0) |
| anti-Polio 2 antibody | 424.6 (342.7 to 526.2) | 388.4 (306.3 to 492.6) |
| anti-Polio 3 antibody | 730.6 (596.5 to 894.9) | 775.6 (645.9 to 931.3) |
Anti-HBs antibody concentrations were expressed as geometric mean concentrations (GMCs) and measured in mIU/mL.
| mIU/ml | dTpa Group | Control Group |
|---|---|---|
| Anti-HBs Antibody Concentrations | 1322.8 (1116.7 to 1567.0) | 1339.2 (1132.8 to 1583.3) |
Anti-PRP antibody concentrations were expressed as GMCs and measured in µg/mL.
| µg/mL | dTpa Group | Control Group |
|---|---|---|
| Anti-PRP Antibody Concentrations | 1.862 (1.554 to 2.231) | 1.717 (1.428 to 2.064) |
Anti-PT, anti-FHA, anti-PRN antibody concentrations were expressed as GMCs and measured in IU/mL.
| IU/mL | dTpa Group | Control Group |
|---|---|---|
| anti-PT antibody | 32.7 (30.2 to 35.3) | 54.7 (51.0 to 58.6) |
| anti-FHA antibody | 68.5 (63.5 to 73.9) | 103.5 (95.6 to 112.1) |
| anti-PRN antibody | 60.5 (54.2 to 67.6) | 92.0 (81.6 to 103.6) |
Assessed anti-pneumococcal serotypes were (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F), expressed as GMCs and measured in µg/mL.
| µg/mL | dTpa Group | Control Group |
|---|---|---|
| anti-PnPS 1 antibody | 1.61 (1.43 to 1.80) | 1.92 (1.73 to 2.14) |
| anti-PnPS 3 antibody | 0.54 (0.49 to 0.60) | 0.60 (0.55 to 0.67) |
| anti-PnPS 4 antibody | 1.20 (1.07 to 1.35) | 1.56 (1.40 to 1.75) |
| anti-PnPS 5 antibody | 1.09 (0.96 to 1.24) | 1.27 (1.13 to 1.43) |
| anti-PnPS 6A antibody | 2.16 (1.89 to 2.47) | 2.59 (2.27 to 2.95) |
| anti-PnPS 6B antibody | 1.37 (1.12 to 1.68) | 1.44 (1.20 to 1.73) |
| anti-PnPS 7F antibody | 2.39 (2.15 to 2.65) | 2.67 (2.43 to 2.93) |
| anti-PnPS 9V antibody | 1.33 (1.19 to 1.50) | 1.64 (1.47 to 1.83) |
| anti-PnPS 14 antibody | 5.70 (4.99 to 6.52) | 6.57 (5.71 to 7.56) |
| anti-PnPS 18C antibody | 1.61 (1.42 to 1.82) | 1.79 (1.59 to 2.01) |
| anti-PnPS 19A antibody | 1.61 (1.43 to 1.82) | 2.01 (1.78 to 2.27) |
| anti-PnPS 19F antibody | 2.57 (2.35 to 2.82) | 3.24 (2.92 to 3.60) |
| anti-PnPS 23F antibody | 0.86 (0.74 to 0.99) | 1.02 (0.88 to 1.17) |
A seropositive subject is a subject whose antibody concentration is ≥ the assay cut-off defined. Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA,2.187 IU/mL for anti-PRN
| Participants | dTpa Group | Control Group |
|---|---|---|
| anti-PT antibody | 266 | 271 |
| anti-FHA antibody | 266 | 271 |
| anti-PRN antibody | 266 | 269 |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Solicited local symptoms were assessed by each and across dose.
| Participants | dTpa Group | Control Group |
|---|---|---|
| Any Pain, Dose 1 | 120 | 120 |
| Any Redness, Dose 1 | 128 | 116 |
| Any Swelling, Dose 1 | 81 | 87 |
| Any Pain, Dose 2 | 109 | 101 |
| Any Redness, Dose 2 | 139 | 139 |
| Any Swelling, Dose 2 | 98 | 95 |
| Any Pain, Dose 3 | 85 | 94 |
| Any Redness, Dose 3 | 122 | 134 |
| Any Swelling, Dose 3 | 77 | 109 |
| Any Pain, Across Doses | 175 | 184 |
| Any Redness, Across Doses | 205 | 203 |
| Any Swelling, Across Doses | 157 | 168 |
Assessed solicited general symptoms were drowsiness, irritability/fussiness, loss of appetite and fever \[defined as axillary route temperature ≥ 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Solicited general symptoms were assessed by each and across dose.
| Participants | dTpa Group | Control Group |
|---|---|---|
| Any Drowsiness, Dose 1 | 166 | 174 |
| Any Irritability / Fussiness, Dose 1 | 187 | 191 |
| Any Loss of Appetite, Dose 1 | 85 | 94 |
| Any Temperature/(Axillary) (≥37.5°C), Dose 1 | 64 | 69 |
| Any Drowsiness, Dose 2 | 142 | 149 |
| Any Irritability / Fussiness, Dose 2 | 182 | 194 |
| Any Loss of Appetite, Dose 2 | 69 | 94 |
| Any Temperature/(Axillary) (≥37.5°C), Dose 2 | 62 | 76 |
| Any Drowsiness, Dose 3 | 99 | 104 |
| Any Irritability / Fussiness, Dose 3 | 142 | 161 |
| Any Loss of Appetite, Dose 3 | 64 | 63 |
| Any Temperature/(Axillary) (≥37.5°C), Dose 3 | 52 | 47 |
| Any Drowsiness, Across Doses | 216 | 232 |
| Any Irritability/Fussiness, Across Doses | 255 | 257 |
| Any Loss of appetite, Across Doses | 142 | 157 |
| Any Temperature/(Axillary) (≥37.5°C), Across Doses | 125 | 126 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
| Participants | dTpa Group | Control Group |
|---|---|---|
| Number of Subjects With Unsolicited Adverse Events | 161 | 173 |
SAEs assessed included medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity.
| Participants | dTpa Group | Control Group |
|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 7 | 17 |
Collected over Solicited symptoms were collected during the 4-day (Day 0-Day 3) follow-up period after each vaccination. Unsolicited AEs were collected during the 31-day (days 0-30) follow-up period after each vaccination. SAEs were collected from Day 0 to Month 3 or 5.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| dTpa Group | 0/296 (0%) | 7/296 (2.4%) | 292/296 (98.6%) |
| Control Group | 0/305 (0%) | 17/305 (5.6%) | 294/305 (96.4%) |
| Event | dTpa Group | Control Group |
|---|---|---|
| BronchiolitisInfections and infestations | 1/296 | 4/305 |
| Congenital cytomegalovirus infectionCongenital, familial and genetic disorders | 1/296 | 0/305 |
| Ear malformationCongenital, familial and genetic disorders | 1/296 | 0/305 |
| Intestinal haemorrhageGastrointestinal disorders | 1/296 | 0/305 |
| Milk allergyImmune system disorders | 1/296 | 0/305 |
| Urinary tract infectionInfections and infestations | 1/296 | 1/305 |
| Skull fractureInjury, poisoning and procedural complications | 1/296 | 0/305 |
| Skull fractured baseInjury, poisoning and procedural complications | 1/296 | 0/305 |
| Altered state of consciousnessNervous system disorders | 1/296 | 0/305 |
| CraniosynostosisCongenital, familial and genetic disorders | 0/296 | 1/305 |
| Event | dTpa Group | Control Group |
|---|---|---|
| Irritability postvaccinalGeneral disorders | 255/296 | 257/305 |
| SomnolenceNervous system disorders | 216/296 | 232/305 |
| Injection site erythemaGeneral disorders | 205/296 | 203/305 |
| Injection site painGeneral disorders | 175/296 | 184/305 |
| Injection site swellingGeneral disorders | 157/296 | 169/305 |
| Decreased appetiteMetabolism and nutrition disorders | 142/296 | 157/305 |
| PyrexiaGeneral disorders | 133/296 | 139/305 |
| Upper respiratory tract infectionInfections and infestations | 36/296 | 32/305 |
| NasopharyngitisInfections and infestations | 20/296 | 15/305 |
| TeethingGastrointestinal disorders | 14/296 | 14/305 |
| Age, Continuous(Weeks) | dTpa Group | Control Group | Total |
|---|---|---|---|
| Mean | 8.7 ± 1.6 | 8.9 ± 1.8 | 8.8 ± 1.7 |
| Sex: Female, Male(Participants) | dTpa Group | Control Group | Total |
|---|---|---|---|
| Female | 141 | 144 | 285 |
| Male | 155 | 161 | 316 |
| Race/Ethnicity, Customized(Participants) | dTpa Group | Control Group | Total |
|---|---|---|---|
| African Heritage / African American | 4 | 9 | 13 |
| Asian - East Asian Heritage | 2 | 0 | 2 |
| Asian - South East Asian Heritage | 3 | 0 | 3 |
| White - Arabic / North African Heritage | 1 | 3 | 4 |
| White - Caucasian / European Heritage | 268 | 285 | 553 |
| Mixed origin | 18 | 8 | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Jan 2016 to primary completion in Mar 2018, 25 months.
Results were first posted in Jun 2019, 1 year 3 months after primary completion.
Of 19 phase 4 interventional studies under Tetanus, half reached primary completion within 22 months of starting (the median); a quarter within 6 and three quarters within 30. This study's 25 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine